Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer's Clinical Syndrome on a Stable Dose of Donepezil

Next Previous
Search
Trial Profile

A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer's Clinical Syndrome on a Stable Dose of Donepezil

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 4334 (Primary) ; Donepezil
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 02 May 2019 Planned End Date changed from 28 Oct 2019 to 28 Feb 2020.
    • 02 May 2019 Planned primary completion date changed from 28 Oct 2019 to 28 Feb 2020.
    • 02 May 2019 Planned initiation date changed from 28 May 2019 to 27 Sep 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top